Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

20051,554 citationsJournal Article

Authors

Ralph A. DeFronzo · The University of Texas Health Science Center at San Antonio

Robert E. Ratner · MedStar Health

Jenny Han · Amplyx Pharmaceuticals (United States)

Dennis Dong Hwan Kim · Amplyx Pharmaceuticals (United States)

Mark Fineman · Amplyx Pharmaceuticals (United States)

Alain Baron · Amplyx Pharmaceuticals (United States)

Abstract

Exenatide was generally well tolerated and reduced HbA(1c) with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin.

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 28, Issue 5, pp. 1092-1100

DOI: 10.2337/diacare.28.5.1092

Field-Weighted Citation Impact: 73.21